Skip to main content

Table 2 Baseline data

From: Impact of menaquinone-4 supplementation on coronary artery calcification and arterial stiffness: an open label single arm study

Hemoglobin (g/dL) 13.8 ± 1.2
Albumin (g/dL) 4.2 ± 0.3
Triglyceride (mg/dL) 136 ± 82
alkaline phosphatase (IU/L) 223 ± 59
Blood urea nitrogen (mg/dL) 15 ± 3
Creatinine (mg/dL) 0.74 ± 0.24
ucOC (ng/ml) 3.7 ± 2.5
OC (ng/ml) 7.5 ± 2.7
ucOC/OC ratio 0.46 ± 0.18
PIVKA2 (mAU/mL) 19 ± 7
intact parathyroid horomone (pg/mL) 38.9 ± 22.0
Bone specific alkaline phosphatase (μg/l) 13.8 ± 6.5
NTX (nmol BCE/L) 16.9 ± 5.1
high sensitive C-reactive protein (mg/L) 929 ± 1132
Osteoprotegerin (ng/mL) 91.7 ± 30.8
oxidized low density lipoprotein (μg/dL) 104.9 ± 11.9
t-ucMGP (nmol/L) 2907 ± 1333
PK (ng/mL) 1.94 ± 1.38
MK-7 (ng/mL) 14.2 ± 11.9
MK-4 (ng/mL) 0.4 ± 2.0
  1. ucOC uncarboxylated osteocalcin
  2. OC osteocalcin
  3. PIVKA2 protein induced by vitamin K absence or antagonist- 2
  4. NTX collagen type 1 cross-linked N-telopeptide
  5. t-ucMGP total circulating uncarboxylated matrix gla protein
  6. PK philloquinone, MK menaquinone